First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Rizvi N. A.; Shepherd F. A.; Antonia S. J.; Brahmer J. R.; Chow L. Q.; Goldman J.; Juergens R.; Borghaei H.; Ready N. E.; Gerber D. E.; Shen Y.; Harbison C.; Chen A. C.; Gettinger S.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

【24h】

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）一线单药治疗晚期非小细胞肺癌（NSCLC）：安全性，有效性以及与PD-L1状态相关的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2014年第5suppla期|共1页
作者
Rizvi N. A.; Shepherd F. A.; Antonia S. J.; Brahmer J. R.; Chow L. Q.; Goldman J.; Juergens R.; Borghaei H.; Ready N. E.; Gerber D. E.; Shen Y.; Harbison C.; Chen A. C.; Gettinger S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status [J] . Rizvi N. A., Shepherd F. A., Antonia S. J., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）一线单药治疗晚期非小细胞肺癌（NSCLC）：安全性，有效性以及与PD-L1状态相关的结果
2. Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) [J] . Gettinger S. N., Horn L., Gandhi L., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）在晚期非小细胞肺癌（NSCLC）患者中的长期生存，临床活性和安全性
3. Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) [J] . Gettinger S., Chow L. Q., Borghaei H., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）加上厄洛替尼对表皮生长因子受体突变（EGFR MT）晚期非小细胞肺癌（NSCLC）患者的安全性和反应
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Nivolumab (anti-PD-1 BMS-936558 ONO-4538) in patients with advanced non-small cell lung cancer [O] . Arun Rajan, James L. Gulley 2014

机译：Nivolumab（anti-PD-1BMS-936558ONO-4538）用于晚期非小细胞肺癌患者
7. Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) [O] . S. Gettinger, L.Q. Chow, H. Borghaei, 2014

机译：Nivolumab的安全性和反应（抗PD-1; BMS-936558，ONO-4538）加上患者（PTS）中的Erlotinib，具有表皮生长因子受体突变体（EGFR MT）先进的非小细胞肺癌（NSCLC）

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

著录项

相似文献

相关主题

期刊订阅